This application is a competing continuation for the Centers for Education and Research on Therapeutics (CERTs) Research Center on cardiovascular disease. The quality of medical care has become a major focus of national health-policy discussions. Continuing improvement in survival and freedom from disability will depend on focusing on better systems for developing therapeutics; demonstrating which therapies are beneficial; and employing them in the right patients. Building on work completed in the first funding cycle of the CERTs, we are dedicated to approaching each element of this """"""""cycle of quality"""""""" -from basic concepts to clinical trials, clinical practice guidelines, quality indicators, performance measurement and finally, outcomes. We will continue to coordinate major clinical trials and outcome studies that translate basic findings into the phase of evaluation (Phase 2 studies) and that definitively demonstrate the efficacy and economic attractiveness of proposed therapies(Phase 3 and 4 studies). We will also embark on a major study of the structure and process of the quality cycle using the example of the ACC/AHA guidelines process, the interaction of NIH/FDA/academia and industry in the formulation of clinical trials and the development of quality indicators. The Duke Health system will be used as a model to study methods of improving adherence to standards of care, and collaborating systems will be used to validate these approaches. Initial trials will evaluate a community pharmacist intervention and the use of a novel internet/voice activated system to share critical data among doctors and patients. Our early work demonstrating the economics of treatment of heart failure will be extended to secondary prevention of coronary artery disease. We will work with the FDA on risk management programs for cardiovascular therapeutic products. Finally, we will continue to train a cadre of investigators, both at the academic site and the practice site, so that the cycle of quality will be improved measurably on a national level.

Agency
National Institute of Health (NIH)
Institute
Agency for Healthcare Research and Quality (AHRQ)
Type
Research Demonstration--Cooperative Agreements (U18)
Project #
5U18HS010548-08
Application #
7120672
Study Section
Special Emphasis Panel (ZHS1-HSR-O (01))
Program Officer
Sedrakyan, Artyom
Project Start
1999-09-30
Project End
2008-03-31
Budget Start
2006-09-30
Budget End
2008-03-31
Support Year
8
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Vavalle, John P; Lopes, Renato D; Chen, Anita Y et al. (2012) Hospital length of stay in patients with non-ST-segment elevation myocardial infarction. Am J Med 125:1085-94
Calvert, Sara Bristol; Kramer, Judith M; Anstrom, Kevin J et al. (2012) Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 163:657-65.e1
Greiner, Melissa A; Hammill, Bradley G; Fonarow, Gregg C et al. (2012) Predicting costs among medicare beneficiaries with heart failure. Am J Cardiol 109:705-11
Alexander, Karen P; Wang, Tracy Y; Li, Shuang et al. (2011) Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care. Circ Cardiovasc Qual Outcomes 4:129-35
Patterson, Mark E; Hernandez, Adrian F; Hammill, Bradley G et al. (2010) Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. Med Care 48:210-6
Hernandez, Adrian F; Hammill, Bradley G; Peterson, Eric D et al. (2010) Relationships between emerging measures of heart failure processes of care and clinical outcomes. Am Heart J 159:406-13
Hammill, Bradley G; Hernandez, Adrian F; Peterson, Eric D et al. (2009) Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 157:995-1000
Allen LaPointe, Nancy M; Zhou, Yi; Stafford, Judith A et al. (2009) Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease. Am J Cardiol 103:1518-24
Tricoci, Pierluigi; Allen, Joseph M; Kramer, Judith M et al. (2009) Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 301:831-41
LaPointe, Nancy M Allen; Stafford, Judith A; Pappas, Paul A et al. (2009) Use of beta-blockers in patients with an implantable cardioverter defibrillator. Ann Pharmacother 43:1189-96

Showing the most recent 10 out of 14 publications